Understanding PD-L1 as a Biomarker in Radiotherapy

Research now confirms that PD-L1 expression in NSCLC serves as a vital prognostic marker for patients receiving stereotactic body radiotherapy (SBRT). While SBRT remains the gold standard for medically inoperable early-stage non-small-cell lung cancer, clinical outcomes vary significantly between individuals. Specifically, clinicians have long sought biomarkers to predict which patients might experience systemic failure despite successful local control. Consequently, this study investigated the role of programmed death-ligand 1 (PD-L1) in predicting recurrence-free and overall survival.

The retrospective analysis involved fifty-four patients whose PD-L1 levels were measured using the SP263 immunohistochemistry assay. Researchers discovered that higher PD-L1 expression, when treated as a continuous variable, independently predicts inferior recurrence-free survival. For instance, each unit increase in expression correlated with a higher hazard ratio for cancer recurrence. Furthermore, using a 2% cutoff significantly distinguished patient outcomes, as those with higher levels faced a six-fold increase in the risk of death.

Clinical Impact of PD-L1 Expression in NSCLC

Although SBRT achieved an excellent two-year local recurrence-free survival rate of 98%, distant progression remains a concern. The study found that patients with high PD-L1 levels were much more likely to suffer from systemic recurrence. Moreover, multivariable analysis confirmed that PD-L1 expression ≥ 2% is an independent predictor of poor overall survival. Therefore, identifying these high-risk patients early allows physicians to consider more aggressive monitoring or potential adjuvant therapies. Because local control is so high, the focus must shift toward managing systemic risks associated with specific biomarkers.

In conclusion, the integration of PD-L1 testing into the pre-treatment workup for SBRT patients offers valuable insights. By understanding the PD-L1 expression in NSCLC, oncologists can better stratify risk and tailor follow-up protocols. This approach ensures that patients at higher risk for systemic failure receive the attention they need to improve long-term survival outcomes.

Frequently Asked Questions

How does PD-L1 expression affect survival after SBRT?

High PD-L1 expression is associated with a significantly higher risk of recurrence and shorter overall survival. Specifically, a 2% cutoff can identify patients at a much higher risk for systemic failure.

Is SBRT still effective if PD-L1 levels are high?

Yes, SBRT provides excellent local control regardless of PD-L1 status, often reaching a 98% local recurrence-free survival rate. However, high PD-L1 levels indicate a higher probability that the cancer may return in other parts of the body.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Park J et al. Programmed Death-Ligand 1 Expression Predicts Poor Prognosis in Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Thorac Cancer. 2026 May undefined. doi: 10.1111/1759-7714.70296. PMID: 42065218.